Skip to main content
Premium Trial:

Request an Annual Quote

Genzyme Molecular Licenses Rights to Affymetrix

Premium

Genzyme Molecular Oncology of Framingham, Mass., has exclusively licensed certain high density DNA array diagnostic and research rights related to the p53 gene to Affymetrix for use on its GeneChip arrays.

Affymetrix currently sells p53 arrays that analyze the coding region of the p53 tumor suppressor gene.

In exchange for exclusive rights to p53 for use on certain diagnostic and research DNA arrays, Genzyme Molecular Oncology will receive from Affymetrix an up-front payment of an undisclosed amount, milestones, and minimum royalties on the sale of future GeneChip products that utilize the p53 gene.

The Affymetrix license will allow GeneChip array customers to conduct microarray-based p53 tests without seeking an additional license from Genzyme.

The p53 gene functions as a tumor suppressor in the human body. Studies have shown that in more than 50 percent of all human cancers the p53 gene is mutated, Genzyme said.

Filed under

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.